194 related articles for article (PubMed ID: 23834917)
1. Differences in immunological responses of polyclonal botulinum A1 and A2 antitoxin against A1 and A2 toxin.
Torii Y; Shinmura M; Kohda T; Kozaki S; Takahashi M; Ginnaga A
Toxicon; 2013 Oct; 73():9-16. PubMed ID: 23834917
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the immunogenicity of botulinum toxin type A and the efficacy of A1 and A2 neurotoxins in animals with A1 toxin antibodies.
Torii Y; Goto Y; Nakahira S; Kozaki S; Ginnaga A
Toxicon; 2014 Jan; 77():114-20. PubMed ID: 24269688
[TBL] [Abstract][Full Text] [Related]
3. Development of an Equine Antitoxin by Immunizing the Halla Horse with the Receptor-Binding Domain of Botulinum Neurotoxin Type A1.
Kim NY; Park KE; Lee YJ; Kim YM; Hong SH; Son WR; Hong S; Lee S; Ahn HB; Yang J; Seo JP; Lim YK; Yu CH; Hur GH; Jeong ST; Lee HS; Song K; Kang TJ; Shin YK; Choi JS; Choi JY
J Microbiol Biotechnol; 2019 Jul; 29(7):1165-1176. PubMed ID: 31280529
[TBL] [Abstract][Full Text] [Related]
4. Anomalous enhancement of botulinum toxin type A neurotoxicity in the presence of antitoxin.
Sheridan RE; Deshpande SS; Amersdorfer P; Marks JD; Smith T
Toxicon; 2001 May; 39(5):651-7. PubMed ID: 11072043
[TBL] [Abstract][Full Text] [Related]
5. Sequence variation within botulinum neurotoxin serotypes impacts antibody binding and neutralization.
Smith TJ; Lou J; Geren IN; Forsyth CM; Tsai R; Laporte SL; Tepp WH; Bradshaw M; Johnson EA; Smith LA; Marks JD
Infect Immun; 2005 Sep; 73(9):5450-7. PubMed ID: 16113261
[TBL] [Abstract][Full Text] [Related]
6. Study on the immunological heterogeneity of Clostridium botulinum B type toxin.
Rymkiewicz D; Sawicki J; Brühl A
Arch Immunol Ther Exp (Warsz); 1979; 27(5):709-14. PubMed ID: 398207
[TBL] [Abstract][Full Text] [Related]
7. Characterization of the monoclonal antibody response to botulinum neurotoxin type A in the complexed and uncomplexed forms.
Zhao H; Nakamura K; Kohda T; Mukamoto M; Kozaki S
Jpn J Infect Dis; 2012; 65(2):138-45. PubMed ID: 22446121
[TBL] [Abstract][Full Text] [Related]
8. [Identification of strain B 657 of Clostridium botulinum].
Giménez DF; Giménez JA
Rev Argent Microbiol; 1983; 15(1):51-5. PubMed ID: 6400761
[TBL] [Abstract][Full Text] [Related]
9. An in vitro cell-based potency assay for pharmaceutical type A botulinum antitoxins.
Torgeman A; Diamant E; Levin L; David AB; Epstein E; Girshengorn M; Mazor O; Rosenfeld R; Zichel R
Vaccine; 2017 Dec; 35(52):7213-7216. PubMed ID: 29174678
[TBL] [Abstract][Full Text] [Related]
10. Comparison of effects of botulinum toxin subtype A1 and A2 using twitch tension assay and rat grip strength test.
Torii Y; Kiyota N; Sugimoto N; Mori Y; Goto Y; Harakawa T; Nakahira S; Kaji R; Kozaki S; Ginnaga A
Toxicon; 2011 Jan; 57(1):93-9. PubMed ID: 21029745
[TBL] [Abstract][Full Text] [Related]
11. Comparison of Systemic Toxicity between Botulinum Toxin Subtypes A1 and A2 in Mice and Rats.
Torii Y; Goto Y; Nakahira S; Kozaki S; Kaji R; Ginnaga A
Basic Clin Pharmacol Toxicol; 2015 Jun; 116(6):524-8. PubMed ID: 25395371
[TBL] [Abstract][Full Text] [Related]
12. Type A1 but not type A2 botulinum toxin decreases the grip strength of the contralateral foreleg through axonal transport from the toxin-treated foreleg of rats.
Torii Y; Akaike N; Harakawa T; Kato K; Sugimoto N; Goto Y; Nakahira S; Kohda T; Kozaki S; Kaji R; Ginnaga A
J Pharmacol Sci; 2011; 117(4):275-85. PubMed ID: 22123262
[TBL] [Abstract][Full Text] [Related]
13. Standardization of the Japanese National Standard, Equine Botulinum Antitoxin Type A, and Factors Affecting Standardization.
Yutani M; Senoh M; Yano H; Kenri T; Iwaki M
Jpn J Infect Dis; 2024 Jan; 77(1):16-20. PubMed ID: 37648491
[TBL] [Abstract][Full Text] [Related]
14. A cell-based alternative to the mouse potency assay for pharmaceutical type E botulinum antitoxins.
Diamant E; Torgeman A; Epstein E; Mechaly A; David AB; Levin L; Schwartz A; Dor E; Girshengorn M; Barnea A; Mazor O; Zichel R
ALTEX; 2022; 39(1):113-122. PubMed ID: 34798660
[TBL] [Abstract][Full Text] [Related]
15. Use of in vitro Vero cell assay and ELISA in the United States potency test of vaccines containing adsorbed diphtheria and tetanus toxoids.
Gupta RK; Siber GR
Dev Biol Stand; 1996; 86():207-15. PubMed ID: 8785950
[TBL] [Abstract][Full Text] [Related]
16. Quantification of potency of neutralizing antibodies to botulinum toxin using compound muscle action potential (CMAP).
Torii Y; Takahashi M; Ishida S; Goto Y; Nakahira S; Harakawa T; Kaji R; Kozaki S; Ginnaga A
Toxicon; 2010; 55(2-3):662-5. PubMed ID: 19781565
[TBL] [Abstract][Full Text] [Related]
17. Purification and characterization of a novel subtype a3 botulinum neurotoxin.
Tepp WH; Lin G; Johnson EA
Appl Environ Microbiol; 2012 May; 78(9):3108-13. PubMed ID: 22367089
[TBL] [Abstract][Full Text] [Related]
18. New equine antitoxins to botulinum neurotoxins serotypes A and B.
Li D; Mattoo P; Keller JE
Biologicals; 2012 Jul; 40(4):240-6. PubMed ID: 22560800
[TBL] [Abstract][Full Text] [Related]
19. An improved method for development of toxoid vaccines and antitoxins.
Jones RG; Liu Y; Rigsby P; Sesardic D
J Immunol Methods; 2008 Aug; 337(1):42-8. PubMed ID: 18571196
[TBL] [Abstract][Full Text] [Related]
20. Mouse compound muscle action potential assay: an alternative method to conduct the LD₅₀ botulinum toxin type A potency test.
Kim SH; Kim SB; Yang GH; Rhee CH
Toxicon; 2012 Sep; 60(3):341-7. PubMed ID: 22613167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
